CA2441099A1 - Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine - Google Patents

Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine Download PDF

Info

Publication number
CA2441099A1
CA2441099A1 CA002441099A CA2441099A CA2441099A1 CA 2441099 A1 CA2441099 A1 CA 2441099A1 CA 002441099 A CA002441099 A CA 002441099A CA 2441099 A CA2441099 A CA 2441099A CA 2441099 A1 CA2441099 A1 CA 2441099A1
Authority
CA
Canada
Prior art keywords
epicatechin
proanthocyanidin
composition
disease
procyanidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002441099A
Other languages
English (en)
Other versions
CA2441099C (fr
Inventor
Alan D. Snow
Gerardo M. Castillo
Paula Y. Choi
Beth P. Nguyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cognitive Clarity Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/938,987 external-priority patent/US6607758B2/en
Priority claimed from US10/053,625 external-priority patent/US6929808B2/en
Application filed by Individual filed Critical Individual
Publication of CA2441099A1 publication Critical patent/CA2441099A1/fr
Application granted granted Critical
Publication of CA2441099C publication Critical patent/CA2441099C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)

Abstract

La présente invention concerne une technique de traitement d'une amylose ou d'une maladie caractérisée par l'.alpha.-synucléine ou par une fibrillogenèse NAC (à composante non amyloïde) chez un mammifère. Cette technique consiste à administrer à ce mammifère une quantité thérapeutiquement efficace de diverses proanthocyanidines de cette invention ou d'une proanthocyanidine caractérisée par les formules générales données dans les spécifications. Cette invention concerne aussi une composition pharmaceutique comprenant une quantité thérapeutiquement efficace de proanthocyanidine et un excipient répondant aux normes pharmaceutiques. Cette quantité thérapeutique de proanthocyanidine est sélectionnée pour son efficacité dans le traitement des amyloses, des maladies induites par l'.alpha.-synucléine ou par des fibrillogenèses NAC chez un mammifère.
CA2441099A 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine Expired - Fee Related CA2441099C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US27686601P 2001-03-15 2001-03-15
US60/276,866 2001-03-15
US09/938,987 US6607758B2 (en) 1997-05-15 2001-08-24 Methods for inhibiting and reducing amyloid fibril formation associated with Alzheimer's Disease and other amyloidoses
US09/938,987 2001-08-24
WOPCT/US01/51131 2001-11-02
US10/053,625 US6929808B2 (en) 2000-11-03 2001-11-02 Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
US10/053,625 2001-11-02
PCT/US2001/051131 WO2002042429A2 (fr) 2000-11-03 2001-11-02 Procedes d'isolement de composes inhibiteurs d'amyloide, et utilisation de composes utilises a partir d'uncaria tomentosa et de plantes parentes
US33872101P 2001-12-04 2001-12-04
US60/338,721 2001-12-04
US33903301P 2001-12-10 2001-12-10
US33896901P 2001-12-10 2001-12-10
US60/338,969 2001-12-10
US60/339,033 2001-12-10
PCT/US2002/004764 WO2002076381A2 (fr) 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine

Publications (2)

Publication Number Publication Date
CA2441099A1 true CA2441099A1 (fr) 2002-10-03
CA2441099C CA2441099C (fr) 2011-04-19

Family

ID=56290250

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2441099A Expired - Fee Related CA2441099C (fr) 2001-03-15 2002-02-15 Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine

Country Status (6)

Country Link
EP (1) EP1377287A4 (fr)
JP (1) JP4380991B2 (fr)
AU (1) AU2002250117B2 (fr)
CA (1) CA2441099C (fr)
NZ (1) NZ528322A (fr)
WO (1) WO2002076381A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
EP1790648A1 (fr) * 2002-10-11 2007-05-30 Proteotech, Inc. Utilisation de procyanidine B2 pour la preparation de médicament pour le traitement des maladies amyloides et synucleines
JP2006232670A (ja) * 2003-05-20 2006-09-07 Ajinomoto Co Inc 神経障害用薬剤
WO2005082351A1 (fr) * 2004-03-02 2005-09-09 Eisai R & D Management Co., Ltd. Agent thérapeutique pour un trouble neurodégénératif
US8263589B2 (en) * 2006-03-29 2012-09-11 Wista Laboratories Ltd. Inhibitors of protein aggregation
WO2009104556A1 (fr) * 2008-02-19 2009-08-27 株式会社岐阜セラツク製造所 Composition
CN105920216A (zh) * 2008-05-09 2016-09-07 西奈山医学院 用于预防和治疗神经退行性疾病的方法
US20140179774A1 (en) * 2012-12-26 2014-06-26 Industrial Technology Research Institute Methods for inhibition of shc-1/p66 to combat aging-related diseases
CA2983091A1 (fr) 2015-05-11 2016-11-17 Meiji Co., Ltd. Composition pour faciliter la production du facteur neurotrophique derive du cerveau
KR102441381B1 (ko) * 2016-07-18 2022-09-07 (주)아모레퍼시픽 3-O-갈로일-3,3',5,5',7-펜타하이드록시플라반(3-O-galloyl-3,3',5,5',7- pentahydroxyflavan)을 포함하는 인지 기능 개선용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4698360B1 (en) * 1985-04-09 1997-11-04 D Investigations Pharmacologiq Plant extract with a proanthocyanidins content as therapeutic agent having radical scavenger effect and use thereof
US6346280B1 (en) * 1997-05-15 2002-02-12 University Of Washington Composition and methods for inhibiting the formation of brain amyloid deposits
CA2289531C (fr) * 1997-05-15 2009-09-29 University Of Washington Composition et procedes de traitement de la maladie d'alzheimer et autres amyloidoses
US5922756A (en) * 1998-02-14 1999-07-13 Chan; Marion Man-Ying Method of inhibiting nitric oxide synthase
CA2322860C (fr) * 1998-03-12 2010-10-19 Mars, Incorporated Produits contenant du ou des polyphenols et de l'arginine-l favorisant la production d'oxyde nitrique
WO2000057707A1 (fr) * 1999-03-15 2000-10-05 Proteotech, Inc. Methodes de traitement de la maladie d'alzheimer et d'autres amyloses avec l'hypericum perforatum et ses derives
WO2001049307A1 (fr) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechines et extrait de the vert destines au traitement de l'amyloidose dans la maladie d'alzheimer et d'autres amyloidoses

Also Published As

Publication number Publication date
AU2002250117B2 (en) 2007-11-29
WO2002076381A3 (fr) 2002-11-21
NZ528322A (en) 2005-03-24
EP1377287A2 (fr) 2004-01-07
CA2441099C (fr) 2011-04-19
EP1377287A4 (fr) 2007-11-14
WO2002076381A2 (fr) 2002-10-03
JP2005505497A (ja) 2005-02-24
JP4380991B2 (ja) 2009-12-09
AU2002250117B8 (en) 2002-10-08

Similar Documents

Publication Publication Date Title
US9133176B2 (en) Isolation, purification and synthesis of procyanidin B2 and uses thereof
US6929808B2 (en) Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants
CA2441099A1 (fr) Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine
US7029710B2 (en) Methods of isolation of amyloid inhibitory ingredients within Uncaria tomentosa
CA2440293A1 (fr) Catechines destinees au traitement de la fibrillogenese dans la maladie d'alzheimer, la maladie de parkinson, l'amylose aa systemique, et autres troubles amyloides
JP2005505497A5 (fr)
AU2002239764A1 (en) Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants
EP2870161B1 (fr) Oxabicycloheptanes et oxabicycloheptènes pour le traitement d'une lésion de reperfusion
JP2004537576A5 (fr)
AU2002250117A1 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
JP5101521B2 (ja) メチシリン耐性黄色ブドウ球菌をオキサシリンに対し感作する組成物および方法
JP2004091390A (ja) 育毛剤
US8496975B2 (en) Compositions for the treatment and prevention of infections of the oral cavity
AU2001278463B2 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
US20050277600A1 (en) Compositions and methods of use of dimer digallates
US20100197778A1 (en) Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US9339488B2 (en) Anti-cervical cancer compound and method of use thereof
EP1921076A1 (fr) synthèse de procyanidine B2

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20200217